{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:05:48Z","timestamp":1790928348912,"version":"4.1.0"},"reference-count":165,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Bone metastases are a major concern in cancer management since they significantly contribute to morbidity and mortality. Metastatic lesions, commonly arising from breast, prostate, lung, and kidney cancers, affect approximately 25% of cancer patients, leading to severe complications such as pain, fractures, and neurological deficits. This narrative review explores contemporary approaches to bone metastases, emphasizing a multidisciplinary strategy and the evolving concept of oligometastatic disease. Oligometastases, defined by limited metastatic spread (1\u20135 lesions), offer a potential window for curative treatment through aggressive interventions, including stereotactic ablative radiotherapy and resection surgery. Tumor boards, integrating systemic therapies with local interventions, are crucial to optimize treatment. Despite promising results, gaps remain in defining optimal treatment sequences and refining patient selection criteria. Future research should focus on personalized approaches, leveraging biomarkers and advanced imaging to enhance outcomes and the quality of life in patients with bone metastases.<\/jats:p>","DOI":"10.3390\/curroncol32040226","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T04:42:07Z","timestamp":1744605727000},"page":"226","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Modern Treatment of Skeletal Metastases: Multidisciplinarity and the Concept of Oligometastasis in the Recent Literature"],"prefix":"10.3390","volume":"32","author":[{"given":"Giulia","family":"Trovarelli","sequence":"first","affiliation":[{"name":"Department of Orthopedics and Orthopedic Oncology, University of Padua, 35122 Padua, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35122 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Viale Europa 11, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia Deborah","family":"Zinnarello","sequence":"additional","affiliation":[{"name":"Department of Orthopedics and Orthopedic Oncology, University of Padua, 35122 Padua, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35122 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariachiara","family":"Cerchiaro","sequence":"additional","affiliation":[{"name":"Department of Orthopedics and Orthopedic Oncology, University of Padua, 35122 Padua, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35122 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8823-448X","authenticated-orcid":false,"given":"Andrea","family":"Angelini","sequence":"additional","affiliation":[{"name":"Department of Orthopedics and Orthopedic Oncology, University of Padua, 35122 Padua, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35122 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pala","sequence":"additional","affiliation":[{"name":"Department of Orthopedics and Orthopedic Oncology, University of Padua, 35122 Padua, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35122 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9617-9882","authenticated-orcid":false,"given":"Pietro","family":"Ruggieri","sequence":"additional","affiliation":[{"name":"Department of Orthopedics and Orthopedic Oncology, University of Padua, 35122 Padua, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35122 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1002\/cam4.2474","article-title":"Are 90% of deaths from cancer caused by metastases?","volume":"8","author":"Rogers","year":"2019","journal-title":"Cancer Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0030-5898(05)70171-1","article-title":"Incidence, Location, and Diagnostic Evaluation of Metastatic Bone Disease","volume":"31","author":"Hage","year":"2000","journal-title":"Orthop. Clin. N. Am."},{"key":"ref_4","first-page":"1489","article-title":"Metastatic carcinoma of the long bones","volume":"76","author":"Riccio","year":"2007","journal-title":"Am. Fam. Physician"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2309499020915989","DOI":"10.1177\/2309499020915989","article-title":"Incidence, prevalence, and outcomes of systemic malignancy with bone metastases","volume":"28","author":"Jiang","year":"2020","journal-title":"J. Orthop. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3322\/canjclin.48.1.6","article-title":"Cancer statistics, 1998","volume":"48","author":"Landis","year":"1998","journal-title":"CA Cancer J. Clin."},{"key":"ref_7","first-page":"87","article-title":"Estimated number of prevalent cases of metastatic bone disease in the US adult population","volume":"87","author":"Li","year":"2012","journal-title":"Clin. Epidemiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of Bone Metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_9","first-page":"3890","article-title":"Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices","volume":"57","author":"Boissier","year":"1997","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10555-007-9109-4","article-title":"The bone microenvironment in metastasis; what is special about bone?","volume":"27","author":"Bussard","year":"2008","journal-title":"Cancer Metastasis Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.31557\/APJCP.2022.23.12.4109","article-title":"Risk Factors, Patterns, and Distribution of Bone Metastases and Skeletal-Related Events in High-Risk Breast Cancer Patients","volume":"23","author":"Anwar","year":"2022","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1053\/j.seminoncol.2010.10.002","article-title":"Implications of Bone Metastases and the Benefits of Bone-Targeted Therapy","volume":"37","author":"Lipton","year":"2010","journal-title":"Semin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2106\/00004623-198668070-00025","article-title":"Metastatic disease of the spine","volume":"68","author":"Harrington","year":"1986","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.hpb.2016.11.002","article-title":"Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: An observational study","volume":"19","author":"Brauer","year":"2017","journal-title":"HPB"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/ejcts\/ezx464","article-title":"Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: A propensity score-matched study\u2020","volume":"53","author":"Tamburini","year":"2018","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_16","first-page":"135","article-title":"Impact of multidisciplinary tumor boards on patients with rectal cancer","volume":"9","author":"Ioannidis","year":"2018","journal-title":"Mol. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.seminoncol.2007.03.002","article-title":"Surgical Therapy of Bone Metastases","volume":"34","author":"Aboulafia","year":"2007","journal-title":"Semin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/iju.13170","article-title":"Skeletal complications in cancer patients with bone metastases","volume":"23","author":"Tsuzuki","year":"2016","journal-title":"Int. J. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrc.2015.01.001","article-title":"Oligometastases: Defined by prognosis and evaluated by cure","volume":"3","author":"Kaneda","year":"2015","journal-title":"Cancer Treat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"26879","DOI":"10.18632\/oncotarget.8568","article-title":"Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib","volume":"7","author":"Lu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1093\/annonc\/mds100","article-title":"Colorectal cancer pulmonary oligometastases: Pooled analysis and construction of a clinical lung metastasectomy prognostic model","volume":"23","author":"Salah","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.injury.2020.11.025","article-title":"New concepts in the surgical treatment of actual and impending pathological fractures in metastatic disease","volume":"54","author":"Cappellari","year":"2023","journal-title":"Injury"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative Radiotherapy for Limited Metastatic Non\u2013Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"djx015","DOI":"10.1093\/jnci\/djx015","article-title":"Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial","volume":"109","author":"Ruers","year":"2017","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non\u2013Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study","volume":"37","author":"Gomez","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1634\/theoncologist.2016-0229","article-title":"Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients","volume":"22","author":"Tolaney","year":"2017","journal-title":"Oncologist"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1097\/JTO.0b013e3181c06980","article-title":"The Role of Histology with Common First-line Regimens for Advanced Non-small Cell Lung Cancer: A Brief Report of the Retrospective Analysis of a Three-arm Randomized Trial","volume":"4","author":"Scagliotti","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/1440-1681.12673","article-title":"Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer","volume":"44","author":"Wang","year":"2017","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000338369","article-title":"Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe Pain","volume":"35","author":"Altundag","year":"2012","journal-title":"Onkologie"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: Causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/14656566.4.4.567","article-title":"Zoledronic acid: An advance in tumour bone disease therapy and a new hope for osteoporosis","volume":"4","author":"Body","year":"2003","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00003495-200363040-00009","article-title":"Zoledronic Acid: A Review of its Use in the Management of Bone Metastases and Hypercalcaemia of Malignancy","volume":"63","author":"Wellington","year":"2003","journal-title":"Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/172460080702200104","article-title":"Clinical Usefulness of Bisphosphonates in Oncology: Treatment of Bone Metastases, antitumoral Activity and Effect on Bone Resorption Markers","volume":"22","author":"Bonginelli","year":"2007","journal-title":"Int. J. Biol. Markers"},{"key":"ref_38","first-page":"109","article-title":"Oral pamidronate in the prevention and treatment of skeletal metastases in patients with breast cancer","volume":"57","author":"Papapoulos","year":"1997","journal-title":"Medicina"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_40","first-page":"417","article-title":"A review of bisphosphonate-associated osteonecrosis of the jaws and its management","volume":"73","author":"Lam","year":"2007","journal-title":"J. Can. Dent. Assoc."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2214\/ajr.183.1.1830017","article-title":"Medial Meniscus Extrusion on Knee MRI: Is Extent Associated with Severity of Degeneration or Type of Tear?","volume":"183","author":"Costa","year":"2004","journal-title":"Am. J. Roentgenol."},{"key":"ref_42","first-page":"w14440","article-title":"Bone targeted therapies in advanced breast cancer","volume":"147","author":"Biskup","year":"2017","journal-title":"Swiss Med. Wkly."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev.med.51.1.377","article-title":"Adjuvant Therapy for Breast Cancer","volume":"51","author":"Hortobagyi","year":"2000","journal-title":"Annu. Rev. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: Mechanism of Action and Role in Clinical Practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos. Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/14737167.2013.820959","article-title":"Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases","volume":"13","author":"Carter","year":"2013","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00774-023-01434-x","article-title":"Metastasis prevention with bone-targeted agents: A complex interaction between the microenvironment and tumour biology","volume":"41","author":"Coleman","year":"2023","journal-title":"J. Bone Miner. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"(2015). Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials. Lancet, 386, 1353\u20131361.","DOI":"10.1016\/S0140-6736(15)60908-4"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/0284186X.2023.2241985","article-title":"Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: A network meta-analysis","volume":"62","author":"Zhou","year":"2023","journal-title":"Acta Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1177\/1078155219877929","article-title":"Bone modifying agents for patients with bone metastases from breast cancer managed in routine practice setting: Treatment patterns and outcome","volume":"26","author":"Zekri","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e7846","DOI":"10.1097\/MD.0000000000007846","article-title":"Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis","volume":"96","author":"Zhang","year":"2017","journal-title":"Medicine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1002\/sim.3977","article-title":"Latent class joint model of ovarian function suppression and DFS for premenopausal breast cancer patients","volume":"29","author":"Zhang","year":"2010","journal-title":"Stat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2147\/IJWH.S69475","article-title":"Clinical utility of exemestane in the treatment of breast cancer","volume":"7","author":"Montemurro","year":"2015","journal-title":"Int. J. Women\u2019s Health"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jbo.2016.05.007","article-title":"Assessment of bone health in breast cancer patients starting adjuvant aromatase inhibitors: A quality improvement clinical audit","volume":"5","author":"Zekri","year":"2016","journal-title":"J. Bone Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/curroncol28020104","article-title":"From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors","volume":"28","author":"Fernandes","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1200\/JCO.2015.64.8675","article-title":"Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial","volume":"34","author":"Ribi","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMc1107198","article-title":"Abiraterone and Increased Survival in Metastatic Prostate Cancer","volume":"365","author":"Berruti","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.ejmech.2016.10.049","article-title":"Design and synthesis of indoline thiohydantoin derivatives based on enzalutamide as antiproliferative agents against prostate cancer","volume":"125","author":"Zuo","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2967\/jnumed.120.259069","article-title":"Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen\u2013Targeted18 F-DCFPyL PET\/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide","volume":"62","author":"Zukotynski","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11255-024-04268-2","article-title":"Efficacy and safety of neoadjuvant chemohormonal therapy for high-risk prostate cancer treated with robot-assisted laparoscopic radical prostatectomy: A propensity score-matched analysis (the MSUG94 group)","volume":"57","author":"Yokoyama","year":"2024","journal-title":"Int. Urol. Nephrol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","article-title":"Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel","volume":"27","author":"Hadji","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1517\/14740338.2012.712108","article-title":"Safety and tolerability of pazopanib in the treatment of renal cell carcinoma","volume":"11","author":"Zivi","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or Carboplatin\u2013Paclitaxel in Pulmonary Adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Zhang, D., Weng, H., Zhu, Z., Gong, W., and Ma, Y. (2024). Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: A comprehensive network meta-analysis and systematic review. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1378993"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41416-024-02751-2","article-title":"QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER\/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial","volume":"131","author":"Zuo","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0093-7754(01)90188-5","article-title":"Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials","volume":"28","author":"Slamon","year":"2001","journal-title":"Semin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.22.02394","article-title":"Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)","volume":"41","author":"Morris","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s11914-021-00689-5","article-title":"Updates in Management of Bone Metastatic Disease in Primary Solid Tumors with Systemic Therapies","volume":"19","author":"Falvello","year":"2021","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in Hormone-Receptor\u2013Positive Advanced Breast Cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.semnuclmed.2014.07.006","article-title":"Radionuclide Therapy for Osseous Metastases in Prostate Cancer","volume":"45","author":"McGrath","year":"2015","journal-title":"Semin. Nucl. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12185-011-0949-x","article-title":"Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma","volume":"94","author":"Abe","year":"2011","journal-title":"Int. J. Hematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hon.2568","article-title":"The acceleration of CAR-T therapy in non-Hodgkin lymphoma","volume":"37","author":"Munshi","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Vanni, S., Caputo, T.M., Cusano, A.M., De Vita, A., Cusano, A., Cocchi, C., Mul\u00e8, C., Principe, S., Liverani, C., and Celetti, G. (Nanoscale, 2025). Engineered anti-HER2 drug delivery nanosystems for the treatment of breast cancer, Nanoscale, Advance Article.","DOI":"10.21203\/rs.3.rs-3891320\/v1"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2147\/IJN.S442768","article-title":"Nanoparticles for the Treatment of Bone Metastasis in Breast Cancer: Recent Advances and Challenges","volume":"19","author":"Yu","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/17425247.2022.2093856","article-title":"Cancer bone metastases and nanotechnology-based treatment strategies","volume":"19","author":"Li","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ncponc0509","article-title":"Mechanisms of Disease: Understanding resistance to HER2-targeted therapy in human breast cancer","volume":"3","author":"Nahta","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"117328","DOI":"10.1016\/j.bone.2024.117328","article-title":"Immune microenvironment of cancer bone metastasis","volume":"191","author":"Hiraga","year":"2025","journal-title":"Bone"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Abbott, A.G., Meyers, D.E., Elmi-Assadzadeh, G., Stukalin, I., Marro, A., Puloski, S.K.T., Morris, D.G., Cheung, W.Y., and Monument, M.J. (2024). Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancer. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1379056"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Angrisani, A., Bosetti, D.G., Vogl, U.M., Castronovo, F.M., and Zilli, T. (2024). Oligometastatic Urothelial Cancer and Stereotactic Body Radiotherapy: A Systematic Review and an Updated Insight of Current Evidence and Future Directions. Cancers, 16.","DOI":"10.3390\/cancers16183201"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"110288","DOI":"10.1016\/j.radonc.2024.110288","article-title":"Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer","volume":"196","author":"Doyle","year":"2024","journal-title":"Radiother. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.euf.2022.08.016","article-title":"The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review","volume":"9","author":"Sargos","year":"2023","journal-title":"Eur. Urol. Focus"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1200\/JCO.2014.55.4675","article-title":"Emergence of Stereotactic Body Radiation Therapy and Its Impact on Current and Future Clinical Practice","volume":"32","author":"Timmerman","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Palma, D.A., Olson, R., Harrow, S., Correa, R.J.M., Schneiders, F., Haasbeek, C.J.A., Rodrigues, G.B., Lock, M., Yaremko, B.P., and Bauman, G.S. (2019). Stereotactic ablative radiotherapy for the comprehensive treatment of 4\u201310 oligometastatic tumors (SABR-COMET-10): Study protocol for a randomized phase III trial. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5977-6"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Olson, R., Mathews, L., Liu, M., Schellenberg, D., Mou, B., Berrang, T., Harrow, S., Correa, R.J.M., Bhat, V., and Pai, H. (2020). Stereotactic ablative radiotherapy for the comprehensive treatment of 1\u20133 Oligometastatic tumors (SABR-COMET-3): Study protocol for a randomized phase III trial. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06876-4"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial","volume":"36","author":"Ost","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.2020.38.6_suppl.116","article-title":"A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)","volume":"38","author":"Tran","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13014-019-1359-0","article-title":"NaF PET\/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy","volume":"14","author":"Hardcastle","year":"2019","journal-title":"Radiat. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1007\/s00259-018-4058-4","article-title":"Prospective comparison of 68Ga-PSMA PET\/CT, 18F-sodium fluoride PET\/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer","volume":"45","author":"Zacho","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s00259-018-4048-6","article-title":"Comparison of [68Ga]Ga-PSMA-11 PET\/CT with [18F]NaF PET\/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy","volume":"45","author":"Uprimny","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.clon.2020.06.018","article-title":"Stereotactic Radiosurgery and Stereotactic Body Radiotherapy in the Management of Oligometastatic Disease","volume":"32","author":"Chen","year":"2020","journal-title":"Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1200\/JCO.24.00081","article-title":"Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial","volume":"42","author":"Ludmir","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2468-1253(23)00316-3","article-title":"Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): An open-label, randomised, phase 2 trial","volume":"9","author":"Liu","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Hitchcock, K.E., Miller, E.D., Shi, Q., Dixon, J.G., Gholami, S., White, S.B., Wu, C., Goulet, C.C., George, M., and Jee, K.-W. (2024). Alliance for clinical trials in Oncology (Alliance) trial A022101\/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: Evaluating radiation, ablation, and surgery (ERASur). BMC Cancer, 24.","DOI":"10.1186\/s12885-024-11899-2"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ijrobp.2022.01.024","article-title":"Cost-Effectiveness of Single Versus Multifraction SABR for Pulmonary Oligometastases: The SAFRON II Trial","volume":"114","author":"Lourenco","year":"2022","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Siva, S., Kron, T., Bressel, M., Haas, M., Mai, T., Vinod, S., Sasso, G., Wong, W., Le, H., and Eade, T. (2016). A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II). BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2227-z"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/jamaoncol.2021.2939","article-title":"Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial","volume":"7","author":"Siva","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1200\/JCO.23.00150","article-title":"Long-Term Outcomes of TROG 13.01 SAFRON II Randomized Trial of Single- Versus Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases","volume":"41","author":"Siva","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Rubini, D., Gagliardi, F., Menditti, V.S., D\u2019Ambrosio, L., Gallo, P., D\u2019Onofrio, I., Pisani, A.R., Sardaro, A., Rubini, G., and Cappabianca, S. (2024). Genetic profiling in radiotherapy: A comprehensive review. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1337815"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/jor.24660","article-title":"Fracture risk assessment and clinical decision making for patients with metastatic bone disease","volume":"38","author":"Damron","year":"2020","journal-title":"J. Orthop. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1245\/s10434-014-4002-1","article-title":"Surgical Management of Bone Metastases: Quality of Evidence and Systematic Review","volume":"21","author":"Wood","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Piccioli, A., Spinelli, M.S., Forsberg, J.A., Wedin, R., Healey, J.H., Ippolito, V., Daolio, P.A., Ruggieri, P., Maccauro, G., and Gasbarrini, A. (2015). How do we estimate survival? External validation of a tool for survival estimation in patients with metastatic bone disease\u2014Decision analysis and comparison of three international patient populations. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1396-5"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00003086-198912000-00027","article-title":"Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures","volume":"249","author":"Mirels","year":"1989","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/1078-0432.CCR-14-2668","article-title":"Treatment Planning and Fracture Prediction in Patients with Skeletal Metastasis with CT-Based Rigidity Analysis","volume":"21","author":"Nazarian","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1007\/s11999-012-2724-6","article-title":"Trends in the Surgical Treatment of Pathologic Proximal Femur Fractures Among Musculoskeletal Tumor Society Members","volume":"471","author":"Steensma","year":"2013","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s11999-011-2047-z","article-title":"Endoprosthetic Treatment is More Durable for Pathologic Proximal Femur Fractures","volume":"470","author":"Steensma","year":"2012","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1302\/0301-620X.87B12.16629","article-title":"Surgical treatment of skeletal metastatic lesions of the proximal femur: Endoprosthesis or Reconstruction Nail?","volume":"87-B","author":"Wedin","year":"2005","journal-title":"J. Bone Jt. Surg. Br."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/00003086-199901000-00016","article-title":"Failures after operation for skeletal metastatic lesions of long bones","volume":"358","author":"Wedin","year":"1999","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s11999-016-4810-7","article-title":"What Are the Functional Results and Complications With Long Stem Hemiarthroplasty in Patients With Metastases to the Proximal Femur?","volume":"475","author":"Peterson","year":"2017","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"209","DOI":"10.21147\/j.issn.1000-9604.2016.02.08","article-title":"Clinical and functional comparison of endoprosthetic replacement with intramedullary nailing for treating proximal femur metastasis","volume":"28","author":"Gao","year":"2016","journal-title":"Chin. J. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s11999-011-2038-0","article-title":"Endoprostheses Last Longer Than Intramedullary Devices in Proximal Femur Metastases","volume":"470","author":"Harvey","year":"2012","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.injury.2018.09.044","article-title":"Treatment of pathologic fractures of the proximal femur","volume":"49","author":"Angelini","year":"2018","journal-title":"Injury"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"919","DOI":"10.21873\/anticanres.15550","article-title":"Outcomes of Intramedullary Nail Fixation for Metastatic Disease: Impending and Pathologic Fractures","volume":"42","author":"Owen","year":"2022","journal-title":"Anticancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/jso.24345","article-title":"Outcome after fixation of metastatic proximal femoral fractures: A systematic review of 40 studies: Metastatic Proximal Femoral Fractures","volume":"114","author":"Janssen","year":"2016","journal-title":"J. Surg. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/S0020-1383(17)30658-7","article-title":"Is endoprosthesis safer than internal fixation for metastatic disease of the proximal femur? A systematic review","volume":"48","author":"Martinelli","year":"2017","journal-title":"Injury"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/CORR.0000000000000630","article-title":"Causes and Frequencies of Reoperations After Endoprosthetic Reconstructions for Extremity Tumor Surgery: A Systematic Review","volume":"477","author":"Thornley","year":"2019","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/jso.25218","article-title":"Pathologic fractures of the distal femur: Current concepts and treatment options","volume":"118","author":"Willeumier","year":"2018","journal-title":"J. Surg. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00590-016-1764-0","article-title":"Reconstruction of the proximal femur with a modular resection prosthesis","volume":"26","author":"Piraino","year":"2016","journal-title":"Eur. J. Orthop. Surg. Traumatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1097\/CORR.0000000000000899","article-title":"What Is the Survival and Function of Modular Reverse Total Shoulder Prostheses in Patients Undergoing Tumor Resections in Whom an Innervated Deltoid Muscle Can Be Preserved?","volume":"477","author":"Trovarelli","year":"2019","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5152\/j.aott.2021.20101","article-title":"Limb salvage surgery of primary and metastatic bone tumors of the lower extremity: Functional outcomes and survivorship of modular endoprosthetic reconstruction","volume":"55","author":"Topkar","year":"2021","journal-title":"Acta Orthop. Traumatol. Turc."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1097\/CORR.0000000000002669","article-title":"What Is the Prosthetic Survival After Resection and Intercalary Endoprosthetic Reconstruction for Diaphyseal Bone Metastases of the Humerus and Femur?","volume":"481","author":"Johnson","year":"2023","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jso.22061","article-title":"Survival analysis of patients with femoral metastases","volume":"105","author":"Mavrogenis","year":"2012","journal-title":"J. Surg. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s10147-022-02144-6","article-title":"The role of surgery in the treatment of metastatic bone tumor","volume":"27","author":"Hayashi","year":"2022","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Forsberg, J.A., Wedin, R., Bauer, H.C., Hansen, B.H., Laitinen, M., Trovik, C.S., Keller, J.\u00d8., Boland, P.J., and Healey, J.H. (2012). External validation of the Bayesian Estimated Tools for Survival (BETS) models in patients with surgically treated skeletal metastases. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-493"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1007\/s11999-016-5187-3","article-title":"Can We Estimate Short- and Intermediate-term Survival in Patients Undergoing Surgery for Metastatic Bone Disease?","volume":"475","author":"Forsberg","year":"2017","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1002\/jor.24763","article-title":"Validation of PATHFx 2.0: An open-source tool for estimating survival in patients undergoing pathologic fracture fixation","volume":"38","author":"Overmann","year":"2020","journal-title":"J. Orthop. Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/jso.23654","article-title":"Prognostic role of en-bloc resection and late onset of bone metastasis in patients with bone-seeking carcinomas of the kidney, breast, lung, and prostate: SSG study on 672 operated skeletal metastases: Surgery of Bone Metastases","volume":"110","author":"Ratasvuori","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_134","first-page":"90","article-title":"Surgical Management of Metastatic Long Bone Fractures: Principles and Techniques","volume":"22","author":"Scolaro","year":"2014","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1302\/0301-620X.83B4.0830471","article-title":"The treatment of metastases in the appendicular skeleton","volume":"83-B","author":"Capanna","year":"2001","journal-title":"J. Bone Jt. Surg. Br."},{"key":"ref_136","first-page":"185","article-title":"Tratamiento quir\u00fargico de las met\u00e1stasis \u00f3seas en el esqueleto apendicular","volume":"62","year":"2018","journal-title":"Rev. Esp. Cir. Ortop\u00e9dica Traumatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0030-5898(20)31040-3","article-title":"Surgical management of secondary neoplastic fractures about the hip","volume":"5","author":"Murray","year":"1974","journal-title":"Orthop. Clin. N. Am."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00066-019-01528-4","article-title":"Lokal konsolidierende Strahlentherapie beim oligometastasierten Nicht-kleinzelligen Bronchialkarzinom","volume":"195","author":"Fabian","year":"2019","journal-title":"Strahlenther. Onkol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"6327","DOI":"10.1245\/s10434-022-12239-z","article-title":"Intervention for Hepatic and Pulmonary Metastases in Breast Cancer Patients: Prospective, Multi-institutional Registry Study\u2013IMET, Protocol MF 14-02","volume":"29","author":"Soran","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Ferriero, M., Cacciatore, L., Ochoa, M., Mastroianni, R., Tuderti, G., Costantini, M., Anceschi, U., Misuraca, L., Brassetti, A., and Guaglianone, S. (2023). The Impact of Metastasectomy on Survival Outcomes of Renal Cell Carcinoma: A 10-Year Single Center Experience. Cancers, 15.","DOI":"10.3390\/cancers15133332"},{"key":"ref_141","first-page":"T389","article-title":"[Translated article] Oligometastases in oncological orthopaedic surgery. Our experience","volume":"66","year":"2022","journal-title":"Rev. Esp. Cir. Ortop\u00e9dica Traumatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2106\/JBJS.19.00936","article-title":"A Novel Tripod Percutaneous Reconstruction Technique in Periacetabular Lesions Caused by Metastatic Cancer","volume":"102","author":"Yang","year":"2020","journal-title":"J. Bone Jt. Surg."},{"key":"ref_143","first-page":"503","article-title":"Ablation, Osteoplasty, Reinforcement, and Internal Fixation for Percutaneous Endoskeletal Reconstruction of Periacetabular and Other Periarticular Osteolytic Metastases","volume":"70","author":"Toombs","year":"2021","journal-title":"Instr. Course Lect."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Angelini, A., D\u2019Amico, A., Paolilli, S., Signori, R., Baldin, G., Di Rubbo, G., Denaro, L., and Ruggieri, P. (2024). Electrochemotherapy in Spine Metastases: A Case Series Focused on Technical Aspects, Surgical Strategies and Results. Diagnostics, 14.","DOI":"10.3390\/diagnostics14090936"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jvir.2019.11.029","article-title":"Minimally Invasive Image-Guided Ablation, Osteoplasty, Reinforcement, and Internal Fixation (AORIF) for Osteolytic Lesions in the Pelvis and Periarticular Regions of Weight-Bearing Bones","volume":"31","author":"Lee","year":"2020","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.3390\/curroncol29080411","article-title":"Treatment of Bone Metastasis","volume":"29","author":"Errani","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/PPO.0000000000000438","article-title":"Prognostic and Predictive Biomarkers in Oligometastatic Disease","volume":"26","author":"Barnum","year":"2020","journal-title":"Cancer J."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s11912-024-01515-8","article-title":"An Update on the Management of Bone Metastases","volume":"26","author":"Grosinger","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijrobp.2019.12.041","article-title":"Patient-Reported Outcomes of Oligometastatic Patients After Conventional or Stereotactic Radiation Therapy to Bone Metastases: An Analysis of the PRESENT Cohort","volume":"107","author":"Pielkenrood","year":"2020","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1007\/s00520-022-06990-y","article-title":"3-T magnetic resonance\u2013guided high-intensity focused ultrasound (3 T-MR-HIFU) for the treatment of pain from bone metastases of solid tumors","volume":"30","author":"Bongiovanni","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40349-018-0117-3","article-title":"Focused ultrasound for the treatment of bone metastases: Effectiveness and feasibility","volume":"6","author":"Bertrand","year":"2018","journal-title":"J. Ther. Ultrasound"},{"key":"ref_152","unstructured":"(2024, September 01). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Kidney Cancer Version 2.2023. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf."},{"key":"ref_153","unstructured":"(2024, September 01). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Prostate Cancer Version 4.2022. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"ref_154","unstructured":"(2024, September 01). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Non-Small Cell Lung Cancer Version 3.2022. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"key":"ref_155","unstructured":"(2024, September 01). ESMO Consensus Guidelines for the Management of Patients with Metastatic Colorectal Cancer. Available online: https:\/\/www.annalsofoncology.org\/article\/S0923-7534(19)34754-4\/pdf."},{"key":"ref_156","unstructured":"(2024, September 01). ESMO Clinical Practice Guidelines Metastatic NSCLC. Available online: https:\/\/www.esmo.org\/content\/download\/347819\/6934778\/1\/ESMOCPG-mNSCLC-15SEPT2020.pdf."},{"key":"ref_157","first-page":"123","article-title":"Recognition of and treatment recommendations for oligometastatic disease in multidisciplinary tumor boards","volume":"38","author":"Christ","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000495474","article-title":"Multidisciplinary Tumor Board Recommendations for Oligometastatic Malignancies: A Prospective Single-Center Analysis","volume":"42","author":"Galata","year":"2019","journal-title":"Oncol. Res. Treat."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4254\/wjh.v11.i2.150","article-title":"Colorectal liver metastases: An update on multidisciplinary approach","volume":"11","author":"Chow","year":"2019","journal-title":"World J. Hepatol."},{"key":"ref_160","first-page":"585","article-title":"Retrospective analysis of patients with rare-site and metastatic giant cell tumor","volume":"25","author":"Liu","year":"2013","journal-title":"Chin J. Cancer Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"21057","DOI":"10.1002\/cam4.6667","article-title":"Active involvement of patients, radiation oncologists, and surgeons in a multidisciplinary team approach: Guiding local therapy in recurrent, metastatic rectal cancer","volume":"12","author":"Choi","year":"2023","journal-title":"Cancer Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.clcc.2021.10.009","article-title":"Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer","volume":"21","author":"Lee","year":"2022","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Brown, G.T.F., Bekker, H.L., and Young, A.L. (2022). Quality and efficacy of Multidisciplinary Team (MDT) quality assessment tools and discussion checklists: A systematic review. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09369-8"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"28","DOI":"10.21037\/cco-23-118","article-title":"Oligometastatic disease: A need for consensus to cure the incurable in a multidisciplinary approach","volume":"13","author":"Barba","year":"2024","journal-title":"Chin. Clin. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1245\/s10434-024-16471-7","article-title":"Do Surgical Oncology Multidisciplinary Team Meetings Make a Difference?","volume":"32","author":"Smith","year":"2025","journal-title":"Ann. Surg. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/4\/226\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:13:06Z","timestamp":1760029986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/4\/226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":165,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["curroncol32040226"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32040226","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}